ImP is a histidine-derived metabolite elevated in prediabetic and T2DM patients [132], and has been shown to impair insulin signaling by activating mTORC1 and increasing Ser phosphorylation of IRS-1 [142]. Here, INS is linked to type 2 diabetes mellitus.